Omacor and Senna drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Omacor (omega-3acid ethyl esters) and Senna (senna). Common drug interactions include lower respiratory tract infection among females and myopathy among males.

The phase IV clinical study analyzes what interactions people have when they take Omacor and Senna. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Omacor?

Omacor has active ingredients of omega-3acid ethyl esters. It is often used in high blood cholesterol. eHealthMe is studying from 2,547 Omacor users. Check the latest studies of Omacor.

What is Senna?

Senna has active ingredients of senna. It is often used in constipation. eHealthMe is studying from 37,302 Senna users. Check the latest studies of Senna.



On Jul, 13, 2026

39 people who take Omacor and Senna together, and have interactions are studied.

Omacor and Senna drug interactions.

What are the common drug interactions of Omacor and Senna, by gender? *:

female:

  1. Lower respiratory tract infection
  2. Mobility decreased (ability to move is reduced)
  3. Neutrophil count increased (excess than normal number of neutrophil a type of blood cell)
  4. Platelet count increased
  5. Pleural effusion (water on the lungs)
  6. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  7. White blood cell count increased
  8. Glomerular filtration rate decreased
  9. Muscle atrophy (a decrease in the mass of the muscle)
  10. Urticaria (rash of round, red welts on the skin that itch intensely)

male:

  1. Myopathy (a muscular disease in which the muscle fibres do not function)
  2. Myositis (inflammation of the muscles)
  3. Cellulitis of male external genital organ (infection of male genitals soft tissue)
  4. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  5. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  6. Colon gangrene (colon tissue dies)
  7. Deafness unilateral
  8. Deformity (disfigurement)
  9. Diarrhoea
  10. Eye movement disorder

What are the common drug interactions of Omacor and Senna, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Rectal abscess (pus in rectum)
  2. Scar
  3. Scrotal abscess (pus in scrotum)
  4. Sepsis (a severe blood infection that can lead to organ failure and death)
  5. Necrosis (the death of body tissue)
  6. Necrotising fasciitis (an uncommon life-threatening soft-tissue infection)
  7. Chronic kidney disease
  8. Haemoglobin decreased
  9. Mean cell volume decreased (less of the average red blood cell volume)
  10. Renal failure (kidney dysfunction)

50-59:

  1. Lower respiratory tract infection
  2. Antipsychotic drug level increased
  3. Empyema (collection of pus in a cavity in the body)
  4. Neutrophil count increased (excess than normal number of neutrophil a type of blood cell)
  5. Platelet count increased
  6. Pleural effusion (water on the lungs)
  7. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  8. White blood cell count increased
  9. Confusional state
  10. Drug level increased

60+:

  1. Malaise (a feeling of general discomfort or uneasiness)
  2. Fatigue (feeling of tiredness)
  3. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  4. Peripheral swelling
  5. Pruritus (severe itching of the skin)
  6. Skin depigmentation (lightening of the skin)
  7. Vasodilatation (widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls)
  8. Vision blurred
  9. Weight decreased
  10. Ear disorder

What are the existing conditions these people have? *

  1. Escherichia Urinary Tract Infection (urinary tract infection by escherichia coli): 14 people, 35.90%
  2. High Blood Pressure: 11 people, 28.21%
  3. Pain: 10 people, 25.64%
  4. Depression: 10 people, 25.64%
  5. Hyperlipidaemia (presence of excess lipids in the blood): 9 people, 23.08%
  6. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 5 people, 12.82%
  7. Type 2 Diabetes: 4 people, 10.26%
  8. Indigestion: 4 people, 10.26%
  9. Weight Decreased: 3 people, 7.69%
  10. Hypotension (abnormally low blood pressure): 3 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Omacor and Senna?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Omacor and Senna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Omacor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Senna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Omacor and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Senna and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on omega-3acid ethyl esters and senna (the active ingredients of Omacor and Senna, respectively), and Omacor and Senna (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: